A5081867583- Hormonal Regulation and Hypertension
- ATP Synthase and ATPases Research
- Alzheimer's disease research and treatments
- Cholinesterase and Neurodegenerative Diseases
- Diabetes and associated disorders
- Aldose Reductase and Taurine
- Biochemical Acid Research Studies
- Adrenal Hormones and Disorders
- Estrogen and related hormone effects
- Mitochondrial Function and Pathology
University of Hradec Králové
2018-2023
University Hospital Hradec Králové
2018-2020
It has long been established that mitochondrial dysfunction in Alzheimer’s disease (AD) patients can trigger pathological changes cell metabolism by altering metabolic enzymes such as the 17β-hydroxysteroid dehydrogenase type 10 (17β-HSD10), also known amyloid-binding alcohol (ABAD). We and others have shown frentizole riluzole derivatives inhibit 17β-HSD10 this inhibition is beneficial holds therapeutic merit for treatment of AD. Here we evaluate several novel series based on...
Several neurodegenerative disorders including Alzheimer's disease (AD) have been connected with deregulation of casein kinase 1 (CK1) activity. Inhibition CK1 therefore presents a potential therapeutic strategy against such pathologies. Recently, novel class CK1-specific inhibitors N-(benzo[d]thiazol-2-yl)-2-phenylacetamide structural scaffold has discovered. 1-(benzo[d]thiazol-2-yl)-3-phenylureas, on the other hand, are known amyloid-beta binding alcohol dehydrogenase (ABAD), an enzyme also...
Human 17β-hydroxysteroid dehydrogenase type 10 is a multifunctional protein involved in many enzymatic and structural processes within mitochondria. This enzyme was suggested to be several neurological diseases, e.g., mental retardation, Parkinson’s disease, or Alzheimer’s which it shown interact with the amyloid-beta peptide. We prepared approximately 60 new compounds based on benzothiazolyl scaffold evaluated their inhibitory ability mechanism of action. The most potent inhibitors...